Title: Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma
Authors: Sch√∂ffski, Patrick ×
Wolter, Pascal
Clement, Paul
Sciot, Raphael
De Wever, Ivo
Wozniak, Agnieszka
Stefan, Cristiana
Dumez, Herlinde #
Issue Date: Aug-2007
Publisher: Future Medicine Ltd., UK
Series Title: Future Oncology vol:3 issue:4 pages:381-392
Abstract: Trabectedin (ET-743; Yondelis) is a novel DNA-binding agent, originally derived from the marine tunicate, Ecteinascidia turbinata, and now produced synthetically. The efficacy of trabectedin in patients with advanced soft-tissue sarcoma has been demonstrated in three Phase II studies involving 189 previously treated patients. A pooled analysis of data from these studies showed that trabectedin induced tumor control (objective responses plus disease stabilization) in approximately 50% of patients; median overall survival was 10.3 months and progression-free survival at 6 months was 19.8%, with 29.3% of patients alive at 2 years. Responses were achieved in patients who were resistant to both doxorubicin and ifosfamide. Trabectedin is generally well tolerated, with adverse events being non cumulative, reversible and manageable. Unlike other commonly used cytotoxic agents, trabectedin is not associated with cardiotoxicity or neurotoxicity and alopecia is rare. Trabectedin is an interesting new anticancer agent that offers much promise for the treatment of advanced soft-tissue sarcoma.
ISSN: 1479-6694
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
Clinical Residents Medicine
Translational Cell & Tissue Research
Surgical Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.